Aileron Therapeutics Announces First Patients Treated in Phase Ib Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast Cancer

Aileron Therapeutics announced it has treated the first patients in its Phase Ib randomized, controlled clinical trial evaluating ALRN-6924 to protect against chemotherapy-induced bone marrow toxicities, as well as other toxicities in patients with p53-mutated breast cancer.